Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML

Autor:	Ursula Creutzig, S Diekamp, Dirk Reinhardt, Martin Zimmermann
Rok vydání:	2007
Předmět:	Male medicine.medical_specialty Adolescent Drug-Related Side Effects and Adverse Reactions Heart Diseases Anthracycline Daunorubicin medicine.medical_treatment Cardiomyopathy Pilot Projects Time Risk Factors hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Anthracyclines Cumulative incidence Longitudinal Studies Survivors Child Subclinical infection Cardiotoxicity Chemotherapy Dose-Response Relationship Drug Cumulative dose business.industry Infant Heart Hematology medicine.disease Treatment Outcome Oncology Echocardiography Leukemia Myeloid Child Preschool Acute Disease Pediatrics Perinatology and Child Health Cardiology Female business Follow-Up Studies medicine.drug
Zdroj:	Pediatric Blood & Cancer. 48:651-662
ISSN:	1545-5017 1545-5009
DOI:	10.1002/pbc.21105
Popis:	Background Anthracyclines are effective antineoplastic drugs in acute myelogenous leukemia (AML). However, their use is limited by cardiomyopathy, which occurs in children already at cumulative doses of 300 mg/m2 (given as daunorubicin equivalent). Procedure To evaluate anthracycline-associated cardiomyopathy in pediatric AML-patients, the incidence of early and late (>1 year after intensive AML chemotherapy) clinical and subclinical cardiotoxicity was analyzed out of a total of 1,207 patients
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::795e4bbe4d34bd1bb8eabec5ee633e14 https://doi.org/10.1002/pbc.21105 Zobrazit plný text záznamu Plný text